Our results were consistent with the consensus that STK11 and KEAP1 mutations are associated with an immunosuppressive tumor microenvironment [23, 24], but the findings were inconsistent with a retrospective study investigating whether the KRAS status could affect the efficacy of PD-(L)1 inhibitors among 1,261 patients with STK11- or KEAP1-mutant lung adenocarcinoma [25]. The gene discussed is KEAP1; the disease is lung adenocarcinoma.